Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
Complete Title: A Randomized Phase II Study Comparing Sequential High dose Testosterone and Enzalutamide to Enzalutamide alone in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer: The STEP-UP Trial (Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression)
Trial Phase: II
Investigator: Michael Schweizer
Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy.
Keywords:
- Prostate Cancer, Castration-resistant (CRPC)
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
II
Michael Schweizer
RG1122822
NCT04363164
A Randomized Phase II Study Comparing Sequential High dose Testosterone and Enzalutamide to Enzalutamide alone in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer: The STEP-UP Trial (Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression)
Prostate Cancer, Castration-resistant (CRPC)